Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer

Liang et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69dd59a70a7b4bc8c4101810 — DOI: https://doi.org/10.1097/js9.0000000000000738

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery· 2021 · 2,133 citations
2. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial· 2021 · 290 citations
3. Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.· 2022 · 2 citations
4. Perspectives of laparoscopic surgery for gastric cancer· 2022 · 15 citations
5. Imaging in assessing lymph node status in gastric cancer· 2009 · 281 citations